title: Mistletoe lectins enhance immune responses to intranasally co-administered herpes simplex virus glycoprotein D2.
abstract: The mucosal adjuvant properties of the three type 2 ribosome-inactivating proteins (RIPs) from the European mistletoe, Viscum album L., were investigated. Mistletoe lectins were compared with cholera toxin (CT) as adjuvants when delivered nasotracheally together with herpes simplex virus glycoprotein D2 (gD2). All three mistletoe lectins (MLI, MLII, MLIII) were potent mucosal adjuvants. Co-administration of MLI, MLII or MLIII with gD2 led to significantly higher levels of gD2-specific mucosal immunoglobulin A (IgA) and systemic immunoglobulin G (IgG) antibody than when the antigen was delivered alone. The levels of antibodies induced were similar to those generated in mice immunized with gD2 and the potent mucosal adjuvant CT. Administration of ML1 with gD2 enhanced the antigen-specific splenic T-cell proliferative response. Interleukin-5 (IL-5), but not interferon-gamma (IFN-gamma), was detected in supernatants from splenocytes stimulated in vitro with gD2. This indicates that MLI enhanced type 2 T-helper cell (Th2) responses to the bystander antigen, gD2. Analysis of the gD2- and lectin-specific IgG subclass titres in mice immunized with gD2 and MLI, MLII or MLIII revealed a high ratio of IgG1 : IgG2a, which is compatible with the selective induction of Th2-type immune responses.
authors.affiliation: Rowett Research Institute, Bucksburn, Aberdeen, Scotland, UK. lavellee@tcd.ie
authors.forename: E C
authors.initials: EC
authors.lastname: Lavelle
authors.forename: G
authors.initials: G
authors.lastname: Grant
authors.forename: A
authors.initials: A
authors.lastname: Pusztai
authors.forename: U
authors.initials: U
authors.lastname: Pfüller
authors.forename: O
authors.initials: O
authors.lastname: Leavy
authors.forename: E
authors.initials: E
authors.lastname: McNeela
authors.forename: K H G
authors.initials: KH
authors.lastname: Mills
authors.forename: D T
authors.initials: DT
authors.lastname: O'Hagan
mesh_terms: D000276:Adjuvants, Immunologic; D000281:Administration, Intranasal; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D002455:Cell Division / Q000276:immunology; D016207:Cytokines / Q000096:biosynthesis; D005260:Female; D022301:Herpes Simplex Virus Vaccines / Q000276:immunology*; D018928:Immunity, Mucosal; D007114:Immunization / Q000379:methods; D007070:Immunoglobulin A / Q000096:biosynthesis; D007074:Immunoglobulin G / Q000096:biosynthesis; D051379:Mice; D008807:Mice, Inbred BALB C; D014784:Mistletoe / Q000276:immunology; D037121:Plant Lectins / Q000276:immunology*; D028321:Plant Preparations / Q000276:immunology*; D010940:Plant Proteins; D054790:Ribosome Inactivating Proteins, Type 2; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology; D014118:Toxins, Biological / Q000276:immunology*; D014759:Viral Envelope Proteins / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D016207:Cytokines; D022301:Herpes Simplex Virus Vaccines; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D037121:Plant Lectins; D028321:Plant Preparations; D010940:Plant Proteins; D054790:Ribosome Inactivating Proteins, Type 2; D014118:Toxins, Biological; D014759:Viral Envelope Proteins; C039447:glycoprotein D, Human herpesvirus 1; C009674:ribosome inactivating protein, Viscum